Amyloid PET Imaging & Alzheimer's Infusion Therapy in Oklahoma City

Amyloid PET (Positron Emission Tomography) imaging uses a small amount of a radioactive tracer to highlight amyloid plaque in the brain — a key indicator linked to memory loss and cognitive decline. Because amyloid buildup can begin years before symptoms appear, this imaging allows for early, proactive diagnosis. Amyloid Brain Imaging is now CMS-approved.

We offer FDA-approved Targeted Monoclonal Infusion Therapy designed to remove amyloid plaque from the brain: Kisunla (Eli Lilly), administered once monthly, and Leqembi (Eisai), administered every two weeks. These therapies address the underlying cause of Alzheimer's, not just the symptoms, and are CMS and Medicare approved.

Yes. Medicare (CMS) covers amyloid PET brain scans when ordered by a doctor to diagnose or manage cognitive impairment and Alzheimer's disease — and CMS has removed its earlier restriction that limited coverage to a single scan per lifetime or to clinical trials only. Our Kisunla and Leqembi infusion treatments are also CMS and Medicare approved. Contact our office to verify your specific coverage.

Cardiac PET is an advanced, noninvasive imaging tool that evaluates blood flow and function of the heart. It includes Myocardial Perfusion Imaging (MPI) — the preferred test of the American Society of Nuclear Cardiology (ASNC) — to detect coronary artery disease (CAD), assess myocardial viability, and guide personalized treatment plans. Compared to traditional stress tests, it offers clearer images, faster results, low radiation exposure, and improved diagnostic accuracy.

Common early signs include trouble finding the right words, occasional mistakes managing finances or bills, forgetting appointments or events, trouble recalling time or place, and misplacing important items like keys or a wallet. If you notice these signs, schedule a visit with your primary care provider.

You can request an appointment using the form on this website, or call Hope Alzheimer's Center at (405) 516-4673 or Hope Diagnostic Imaging at (405) 832-4673. Our office is located at 3300 NW 56th St, Oklahoma City, OK 73112, open Monday through Friday, 8am–5pm.

Yes. Brain PET imaging is minimally invasive and involves only a small amount of a radioactive tracer, which highlights areas of amyloid accumulation. The procedure provides a clearer understanding of each patient's condition and helps inform targeted therapy decisions.

Amyloid PET imaging is a highly accurate tool for detecting the brain changes linked to Alzheimer's, with accuracy generally ranging from 85% to 95% and amyloid tracers often showing over 90% sensitivity for detecting plaque. A negative scan can also help rule out Alzheimer's as the cause of symptoms. Results are always interpreted by a physician alongside your symptoms and history.

An amyloid PET scan uses a specialized radioactive tracer that binds specifically to beta-amyloid plaques in the brain. A standard brain PET scan (typically FDG-PET) instead measures how actively brain cells use glucose to assess overall brain function. For Alzheimer's, amyloid PET directly targets the plaque associated with the disease.

Your physician reviews the results alongside your cognitive symptoms and medical history to confirm the diagnosis and discuss treatment options. For eligible patients in early-stage Alzheimer's, this may include FDA-approved infusion therapies such as Leqembi or Kisunla that target and help clear amyloid plaque, plus a personalized care and monitoring plan.

Neither is universally better — MRI and PET serve different purposes and are often used together. An MRI shows detailed brain structure and helps rule out other causes such as stroke, while an amyloid PET scan reveals the beta-amyloid plaque specifically associated with Alzheimer's. Your care team determines the right combination for your situation.

Costs vary by facility, the specific scan, and your insurance. Importantly, Medicare (CMS) now covers amyloid PET brain scans when a physician orders them to evaluate cognitive impairment or Alzheimer's — CMS removed its earlier once-per-lifetime and clinical-trials-only restrictions, and many private insurers are following. Contact our Oklahoma City office to discuss pricing and verify your coverage before scheduling.

Leqembi and Kisunla are both FDA-approved and CMS and Medicare covered for eligible patients with early-stage Alzheimer's. Your out-of-pocket cost depends on your Medicare or insurance plan and any supplemental coverage. Because these are ongoing infusion therapies, we help you understand coverage and expected costs up front — contact our office to verify your benefits.

These infusion therapies are intended for adults with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's, with amyloid plaque confirmed by a PET scan or spinal fluid test. They are generally not used in later-stage disease. Patients on blood thinners, or with certain genetic (ApoE4) or imaging risk factors for brain swelling or small bleeds (ARIA), may need additional evaluation or may not be candidates. A physician determines eligibility after reviewing your history, imaging, and current medications.